NCT04588987

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

A Study to Evaluate the Safety and Efficiency of Using the Neoadjuvant Therapy With Carilizumab and Apatinib in Patients With Recurrent High-Grade Glioma ：A Prospective, Randomized Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the prognosis of glioma patients is still very poor. The study aim to Evaluate the Safety and efficiency of Using the neoadjuvant therapy with Carilizumab and Apatinib in patients with Recurrent High-Grade Glioma.

Conditions

• Neoadjuvant Therapy
• Carilizumab
• Apatinib
• Recurrent High-Grade Glioma

Interventions

Type	Name	Description
BIOLOGICAL	PD-1	Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG

Timeline

• Start date: 2020-10-01
• Primary completion: 2023-10-01
• Completion: 2024-05-01
• First posted: 2020-10-19
• Last updated: 2020-10-19

Locations

1 site across 1 country: China